COVID-19

DGAP-News: ecotel communication ag: ecotel presents half-year figures: continued significant improvement in revenue

Thursday, August 5, 2021 - 8:01am

Net financial assets increased to 5.2 million (12/31/2020: 2.3 million)

Key Points: 
  • Net financial assets increased to 5.2 million (12/31/2020: 2.3 million)
    The first half-year 2021 has been very successful for the ecotel Group.
  • This means that ecotel has been able to achieve substantial increases in consolidated profit and also earnings per share.
  • The easybell segment continued to grow undiminished, in revenue by 19 % to 12.3 million and by 39% in gross profit to 6.9 million.
  • The ecotel Group (hereinafter ecotel), operating throughout Germany since 1998, specializes in the marketing of IT and telecommunications solutions in various segments.

DGAP-News: SUSS MicroTec publishes half-year report 2021: Successful first half-year and confirmation of the outlook for the fiscal year 2021

Thursday, August 5, 2021 - 8:01am

SUSS MicroTec publishes half-year report 2021: Successful first half-year and confirmation of the outlook for the fiscal year 2021

Key Points: 
  • SUSS MicroTec publishes half-year report 2021: Successful first half-year and confirmation of the outlook for the fiscal year 2021
    The issuer is solely responsible for the content of this announcement.
  • The second quarter of the current fiscal year was stronger in terms of both revenue and earnings than the opening quarter.
  • In the first six months of the current fiscal year, revenue was 118.5 million, which is 4.6% higher than in the previous year.
  • As of June 30, 2021, SUSS' net cash position compared to December 31, 2020 increased slightly from 20.3 million to 21.7 million.

DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG closes first half of 2021 with increase in revenues

Thursday, August 5, 2021 - 8:01am

In the first half of 2021, RHN-KLINIKUM AG's efforts to cope with the COVID-19 pandemic continued undiminished.

Key Points: 
  • In the first half of 2021, RHN-KLINIKUM AG's efforts to cope with the COVID-19 pandemic continued undiminished.
  • Dr. Christian Hftberger, Chairman of the Board of Management of RHN-KLINIKUM AG, said: "Once again, the pandemic confronted us with extraordinary tasks.
  • Looking forward, we are confident that we will continue our success in dealing with the related challenges, in particular the economic effects."
  • Revenues within the Group of RHN-KLINIKUM AG in the first half stood at 682.8 million (previous year, 2020: 670.5 million).

Fionet Platform being deployed for COVID-19 Testing at Tennis Canada’s 2021 "National Bank Open presented by Rogers" in Toronto

Thursday, August 5, 2021 - 8:00am

LifeLabs has deployed the Fionet system in advance of the tournament in preparation of testing athletes, officials, tournament employees and other attending personnel.

Key Points: 
  • LifeLabs has deployed the Fionet system in advance of the tournament in preparation of testing athletes, officials, tournament employees and other attending personnel.
  • We are excited to build on our partnership with Fionet Rapid Response Group to support COVID-19 rapid testing at the National Bank Open presented by Rogers, said Charles Brown, President and CEO of LifeLabs.
  • FRRs Fionet provides fast, scalable, quality-controlled testing and real-time digital results for electronic reporting in community-based or decentralized settings.
  • The 2021 National Bank Open presented by Rogers in Toronto will feature the worlds best players on the ATP Tour, including reigning champion and World No.

DGAP-News: Hannover Re continues profitable premium growth and confirms guidance for 2021

Thursday, August 5, 2021 - 7:02am

Hannover, 5 August 2021: Hannover Re substantially increased its Group net income in the first half of 2021 and considers itself well on track to achieve the targets set for the current financial year.

Key Points: 
  • Hannover, 5 August 2021: Hannover Re substantially increased its Group net income in the first half of 2021 and considers itself well on track to achieve the targets set for the current financial year.
  • In property and casualty reinsurance Hannover Re was again able to significantly boost its premium income.
  • The gross written premium in property and casualty reinsurance showed corresponding vigorous growth of 11.9% to reach EUR 10.3 billion (EUR 9.2 billion).
  • Hannover Re, with gross premium of more than EUR 24 billion, is the third-largest reinsurer in the world.

DGAP-News: MAX Automation SE reports strong order intake and improved operating result in first half of 2021

Thursday, August 5, 2021 - 7:01am

Order intake in the Non-Core business (-62.9%) decreased as planned as a result of the closure of the IWM business.

Key Points: 
  • Order intake in the Non-Core business (-62.9%) decreased as planned as a result of the closure of the IWM business.
  • Overall, the MAX Group's order backlog increased by 30.3% to mEUR 234.6 (30 June 2020: mEUR 179.8).
  • Sales at the MAX Group in the first half of 2021 were down 5.2% year-on-year at mEUR 144.2 (H1 2020: mEUR 152.1).
  • MAX Automation expects its portfolio companies in the second half of financial year 2021 to continue to stand their ground in this dynamic environment.

DGAP-News: ElringKlinger posts solid first-half figures across the board

Thursday, August 5, 2021 - 7:01am

The Group generated revenue of EUR 393.6 million, an increase of EUR 141.4 million or 56.1% compared to the same period last year.

Key Points: 
  • The Group generated revenue of EUR 393.6 million, an increase of EUR 141.4 million or 56.1% compared to the same period last year.
  • Without currency effects, revenue would have been up by an additional EUR 19.4 million.
  • After a sharp pandemic-induced drop in revenue in the previous year, there were signs of recovery in all regions.
  • In terms of consolidated earnings, ElringKlinger again anticipates an EBIT margin of around 5 to 6% calculated in relation to Group revenue.

DGAP-News: STS Group AG publishes figures for the first half of 2021 - Positive development in line with management's expectations

Thursday, August 5, 2021 - 7:01am

- Organic revenue growth of 36.9% to 134.8 mEUR (HY/2020: 98.5 mEUR)

Key Points: 
  • - Organic revenue growth of 36.9% to 134.8 mEUR (HY/2020: 98.5 mEUR)
    - Adjusted EBITDA increases to 13.9 mEUR (HY/2020: 2.8 mEUR)
    Hallbergmoos/Munich, August 5, 2021.
  • Andreas Becker, CEO of STS Group AG: "After closing the past financial year on a positive note, we have started the year 2021 in a stronger position.
  • In this respect, the development in the first six months of the current business year was quite positive and in line with our expectations.
  • Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 13.8 mEUR in the first half of 2021 (HY/2020: 1.2 mEUR).

Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Thursday, August 5, 2021 - 7:00am

LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update.

Key Points: 
  • Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
    LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update.
  • In June 2021, Verona Pharma and Nuance Pharma entered into a $219.0 million strategic collaboration to develop and commercialize ensifentrine in Greater China.
  • Verona Pharma will host an investment community conference call at 8:30 a.m.EDT / 1:30 p.m. BST on Thursday, August 5, 2021 to discuss the second quarter 2021 financial results and the corporate update.
  • An electronic copy of the second quarter 2021 results press release will also be made available today on the Companys website.

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Thursday, August 5, 2021 - 6:00am

Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.

Key Points: 
  • Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.
  • Ferinject / Injectafer net sales increased 22.4% (up 22.8% at CER) to CHF 320.5 million in H1 2021 from CHF 261.9 million a year earlier.
  • As a result, Vifor Pharma posted net sales of CHF 73.7 million, up 1.4% or 8.5% at CER.
  • Abbas Hussain was appointed Chief Executive Officer of Vifor Pharma, succeeding Stefan Schulze, who has decided to step down for personal reasons.